Menu
1-702-720-6310 info@microcapspecualtors.com

3 Biotech Long Shots: Boom Or Bust? – Motley Fool


Motley Fool

3 Biotech Long Shots: Boom Or Bust?
Motley Fool
Here’s how Axovant Sciences, Celldex Therapeutics, and Esperion Therapeutics hope to change how doctors treat disease. Todd Campbell. (TMFEBCapital). Feb 24, 2017 at 5:42PM. The ability to develop game-changing new drugs that revolutionize patient …

and more »

Search